11-108327673-C-T
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBP6
The NM_000051.4(ATM):c.7004C>T(p.Thr2335Ile) variant causes a missense change. The variant allele was found at a frequency of 0.0000458 in 1,613,966 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T2335K) has been classified as Likely benign.
Frequency
Consequence
NM_000051.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.7004C>T | p.Thr2335Ile | missense_variant | 48/63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATM | ENST00000675843.1 | c.7004C>T | p.Thr2335Ile | missense_variant | 48/63 | NM_000051.4 | ENSP00000501606.1 |
Frequencies
GnomAD3 genomes AF: 0.000276 AC: 42AN: 152144Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000478 AC: 12AN: 251066Hom.: 0 AF XY: 0.0000369 AC XY: 5AN XY: 135672
GnomAD4 exome AF: 0.0000219 AC: 32AN: 1461704Hom.: 0 Cov.: 30 AF XY: 0.0000179 AC XY: 13AN XY: 727160
GnomAD4 genome AF: 0.000276 AC: 42AN: 152262Hom.: 0 Cov.: 32 AF XY: 0.000309 AC XY: 23AN XY: 74448
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Apr 05, 2017 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Hereditary cancer-predisposing syndrome Uncertain:1Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 30, 2020 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Sep 12, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Mar 17, 2020 | - - |
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 30, 2024 | Variant summary: ATM c.7004C>T (p.Thr2335Ile) results in a non-conservative amino acid change located in the PIK-related kinase, FAT domain (IPR003151) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4.6e-05 in 1613966 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in ATM causing Breast Cancer (4.6e-05 vs 0.001), allowing no conclusion about variant significance. c.7004C>T has been reported in the literature as a VUS in settings of multigene panel testing in individuals affected with breast/prostate cancer and/or therapy related myeloid neoplasms (e.g. Young_2015, Haiman_2013, Singhal_2021), while it has also been reported in a pancreatic cancer case (Yu_2021). These reports do not provide unequivocal conclusions about association of the variant with Breast Cancer/Ataxia Telangiectasia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 23555315, 33850299, 26787654, 35047863). ClinVar contains an entry for this variant (Variation ID: 186867). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Nov 07, 2019 | - - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 14, 2024 | In silico analysis indicates that this missense variant does not alter protein structure/function; Observed in individuals with breast cancer, hematological malignancy, or pancreatic cancer (PMID: 33850299, 23555315, 35047863); This variant is associated with the following publications: (PMID: 26787654, 25530832, 33850299, 23555315, 35047863, 23532176) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Mar 21, 2023 | The frequency of this variant in the general population, 0.00072 (18/24956 chromosomes in African/African American subpopulation, http://gnomad.broadinstitute.org), is higher than would generally be expected for pathogenic variants in this gene. In the published literature, the variant has been reported in individuals with breast cancer (PMID: 26787654 (2016) and 23555315 (2013)), pancreatic cancer (PMID: 35047863 (2022)), and hematological malignancies (PMID: 33850299 (2021)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Familial cancer of breast Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 12, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jun 12, 2024 | This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. - |
ATM-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 27, 2024 | The ATM c.7004C>T variant is predicted to result in the amino acid substitution p.Thr2335Ile. This variant has been previously reported in individuals with breast cancer, prostate cancer, pancreatic cancer, hematological malignancy, and non-small cell lung cancer (Haiman et al. 2013. PubMed ID: 23555315, Table S6.2; Sosonkina et al. 2014. PubMed ID: 25530832, Table S4; Young et al. 2016. PubMed ID: 26787654, Table S1; Singhal et al. 2021. PubMed ID: 33850299, Table S5; Yu et al. 2022. PubMed ID: 35047863). This variant is reported in 0.072% of alleles in individuals of African descent in gnomAD and has conflicting interpretations of likely benign and uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/186867). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Ataxia-telangiectasia syndrome;C0027672:Hereditary cancer-predisposing syndrome Other:1
not provided, no classification provided | phenotyping only | GenomeConnect - Invitae Patient Insights Network | - | Variant interpreted as Uncertain significance and reported on 12-18-2019 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at